SillaJen's BAL0891: A Breakthrough in Cancer Treatment Revealed at ESMO 2026
AI 요약 정보
- SillaJen presents BAL0891 Phase 1 data from 54 patients
- BAL0891-paclitaxel combo: 21.4% response, 78.6% disease control
- BAL0891 monotherapy: one bladder patient has CR >7 months